Pepsi and Other Food Stocks Are Broken. How They Get Back on Track.
Big food companies raised prices more than they needed to during the pandemic, and are now paying the price as consumers look for cheaper—and healthier—alternatives
Verizon Posts Earnings Beat, Stays on Track for Full-Year Outlook
Verizon Communications surpassed expectations with its first-quarter earnings and said it is still on course to meet its yearly goals.
Tariff-Resistant Abbott Laboratories on Track for New Highs
Abbott Laboratories NYSE: ABT is not immune to the impact of tariffs on its medical device business. However, the company's diversified business is tariff-resistant, and moves are being made to strengthen it further.
Verve Therapeutics: FDA Fast Track And Eli Lilly Partnership Upgrade It To A 'Buy'
VERV's VERVE-102 showed an impressive 69% LDL-C reduction in its early Phase 1b data. Also, LLY may opt into VERVE-102's development later this year, which would help VERV by covering one-third of the R&D costs. Similarly, VERV's pipeline includes VERVE-201 for HoFH and refractory hypercholesterolemia, as well as VERVE-301 in collaboration with Lilly.
Arcturus Gets FDA's Fast Track Tag for Influenza Vaccine Candidate
The FDA bestows a Fast Track designation to ARCT's sa-mRNA vaccine candidate, ARCT-2304, for active immunization to prevent pandemic influenza A virus H5N1.
FDA Grants Three Fast Track Tags to Allogene's Autoimmune Disease Drug
The FDA's fast track designations will facilitate rapid development and expedited review of ALLO's autoimmune disease candidate.
Pinnacle Food Group: Not A Buy Yet, But This AgTech IPO Is On The Right Track
Pinnacle Food Group, a hydroponic farming company, is preparing for its IPO amidst a volatile market, targeting urban households and communities with innovative indoor growing systems. The hydroponic farming market is projected to grow significantly due to urbanization and decreasing arable land, with Pinnacle's scalable models and FaaS services positioning it well for growth. Despite impressive revenue growth and strong financials, the IPO valuation appears high; it's recommended to hold off on the IPO and consider buying on the secondary market.
OKYO Pharma CEO discusses FDA Fast Track filing for urcosimod - ICYMI
OKYO Pharma Ltd (NASDAQ:OKYO) CEO Gary Jacob talked with Proactive about the company's recent developments, including the formal naming of its drug candidate OK-101 as urcosimod. Jacob discussed the company's recent Fast Track application to the FDA, aimed at accelerating the regulatory pathway for urcosimod.
Penguin Solutions: Growth Momentum Still On Track
I maintain a bullish rating on Penguin Solutions due to strong AI-related demand and solid financial performance, validated by 2Q25 results. PENG reported $366 million in revenue, up 28% y/y, with significant growth in Advanced Computing and Integrated Memory segments, and improved gross margins. Management's positive pipeline commentary and strong demand from hyperscalers suggest continued revenue growth and successful AI implementations into FY '26.
Intellia: Nex-Z Advancement Remains On Track With Expanded ATTRv-PN Indication
Intellia received RMAT designation from the FDA of nex-z for the treatment of patients with Transthyretin [ATTR] Amyloidosis with Cardiomyopathy. Global sales of the Transthyretin Amyloidosis market is expected to reach $12 billion by 2028. Long-term data from the phase 1/2 study, using NTLA-2002 for the treatment of patients with Hereditary Angioedema, expected in 2025.
TSMC: 2nm Is On Track For Mass Production
Upgrading TSMC to 'Strong Buy' with a fair value of USD$246 per share due to its leading 2nm technology and market recovery potential. TSMC's 2nm production yields reached 60%, with Apple likely to be the first customer, maintaining a first-move advantage over Intel. TSMC's AI business is expected to grow by 100% year-over-year, contributing significantly to its revenue growth in FY25.
Artemis Gold: First Metal Cast, On Track To Commercial Production (Rating Upgrade)
Artemis Gold Inc. receives a 'Buy' rating due to rising gold prices and the first precious metal pour at Blackwater mine. Blackwater mine's transition to production phase and robust growth prospects for precious metals bolster Artemis Gold's profit potential. Artemis Gold's stock price surged by 18.82%, outperforming the S&P 500, driven by positive sentiment and rising gold and silver prices.
